Martin D.
- Country
- Germany
- Department
- Medizinische Klinik und Poliklinik III
Research Overview
- A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1)
- Dose-Escalation and Expansion Study of BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein Degrader, in Patients with B-Cell Malignancies
- Phase 1b/2 Study of MK-1045 Monotherapy and MK-1045 Plus Tocilizumab in Adults with Relapsed/Refractory Non‑Hodgkin Lymphoma
Data & Insights
Has run more than one trial at 235 of 476 partner sites.
Specializations
Lymphoma Research
Specializes in investigating novel treatments for various types of B-cell lymphomas, with particular emphasis on mantle cell lymphoma and diffuse large B-cell lymphoma.
- Targeted Therapies
- Immunotherapy Approaches
- Combination Treatment Strategies
Leads research into innovative therapeutic combinations including BTK inhibitors, rituximab, and novel agents.
Leukemia Studies
Conducts research in chronic lymphocytic leukemia treatment approaches, focusing on combination therapies and novel therapeutic agents.
- Targeted Molecular Therapies
- Immunotherapy Applications
- Treatment Optimization
Investigates advanced therapeutic strategies for previously untreated and relapsed/refractory patients.
Clinical Innovation
Pioneers research in CAR T-cell therapy and other emerging treatments for B-cell malignancies.
- Cell-Based Therapies
- Novel Drug Development
- Treatment Resistance
Evaluates cutting-edge therapeutic approaches including cellular immunotherapy and targeted molecular agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.